. . . . . . . . . . . . "[The results of the study indicated that introducing imatinib into treatment of patients with Ph-positive ALL could improve CR rate and survival, especially as early as possible, and allogenic SCT was still the first choice for these patients if they had suitable donors.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine."@en . . . . . "2014-02-25"^^ . . "Gene-disease associations inferred from text-mining the literature."@en . "DisGeNET evidence - LITERATURE"@en . "2014-10-02T12:40:47+02:00"^^ . . . . . . . . . . . "v2.1.0.0" . "v2.1.0" .